| 6.92 0.16 (2.37%) | 08-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.63 | 1-year : | 9.13 |
| Resists | First : | 7.39 | Second : | 7.82 |
| Pivot price | 7.03  |
|||
| Supports | First : | 6.7 | Second : | 5.58 |
| MAs | MA(5) : | 6.79 |
MA(20) : | 7.12 |
| MA(100) : | 7.04 |
MA(250) : | 8.55 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.6 |
D(3) : | 6.4 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 12.6 | Low : | 6.32 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KYNB ] has closed above bottom band by 36.0%. Bollinger Bands are 13.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.01 - 7.04 | 7.04 - 7.06 |
| Low: | 6.81 - 6.85 | 6.85 - 6.88 |
| Close: | 6.87 - 6.92 | 6.92 - 6.97 |
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Sun, 26 Jul 2026
Kyntra Bio, Inc. (KYNB) Q3 2022 Earnings Report - Results, Call & Slides - TipRanks
Thu, 23 Jul 2026
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-Than-Expected Loss Adds Pressure on Pre-Revenue Biotech - Margin Expansion Trends - dars.gov.et
Mon, 15 Jun 2026
Kyntra Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - Fiscal Year Earnings - po-news-eg.net
Wed, 10 Jun 2026
Kyntra Bio Receives Final Payment for China Divestiture - The Globe and Mail
Tue, 09 Jun 2026
Kyntra Bio receives final $4.0M holdback from AstraZeneca, completes China sale proceeds - TradingView
Mon, 11 May 2026
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.56e+006 (%) |
| Held by Institutions | 2 (%) |
| Shares Short | 115 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.392e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 2 % |
| Operating Margin | 199.4 % |
| Return on Assets (ttm) | -369.1 % |
| Return on Equity (ttm) | -20.2 % |
| Qtrly Rev. Growth | 7.44e+006 % |
| Gross Profit (p.s.) | 37.62 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.94639e+007 |
| Qtrly Earnings Growth | -14 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.63 |
| Dividend | 0 |
| Forward Dividend | 97710 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|